ISKCON Completes Acquisition of Evidence Solution

Shanghai, July 4, 2022, Esco Lifesciences Group (“Esco Lifesciences”, the “Group”), a leading global life science company, announced the acquisition of Evidence Solution (“Evidence”), a Danish assisted reproductive instrument software company.
The company's self-developed software system can monitor the entire process of assisted reproductive treatment, optimize workflow management, and realize intelligent witnessing of the full cycle of assisted reproductive treatment
.
Esco Medical, one of the four business segments of ISK Bio, is the world's leading supplier of assisted reproductive technologies and solutions.
This comprehensive acquisition will further enrich the group's product diversity and increase its global business footprint
.

"Welcome Evidence Solution to the ISKCO family.
As a start-up company established in 2019, the company has achieved rapid growth with its core technology and has accumulated a stable customer base", Chairman and CEO of ISKCO Lin Xiangqian said, "The assisted reproductive industry has a broad market for growth.
Adding Evidence's monitoring technology to ISK's leading assisted reproductive instruments can add new momentum to our product portfolio, and we will provide customers with more innovative and efficient products.
overall solution
.
”

ISKCON has been working on the global assisted reproductive market for more than ten years, and its equipment products have now led the mainstream market in the global assisted reproductive field, including the United States, Europe and China
.
The group is also actively expanding the consumables and reagents products in the upstream field of the assisted reproduction industry.
At the end of 2021, it strategically invested in an assisted reproduction medical device company in China that mainly produces embryo culture medium and egg/sperm processing reagents
.
With the implementation of China's new population policy and the promotion of the macro goal of optimizing the population structure, the assisted reproduction industry still has huge market potential to be released.
Meet today's growing market demands
.
At the same time, the Group will also give full play to the advantages of ISKCON as a bridge between the East and the West, actively seek more strategic cooperation, look for more merger and acquisition opportunities at home and abroad, and continue to promote the deep integration of the East and the West in the field of life sciences
.


About Evidence Solution
Evidence Solution, established in 2019, is a Danish assisted reproductive instrument software company.
The products and software systems it provides can provide traceable and comprehensive monitoring of the assisted reproductive treatment process, helping customers achieve more efficient and accurate work.
Process management
.


About ISK Bio

ISKBio is a leading global life sciences company established in Singapore, focusing on providing core life tools and services for academic research, scientific research, clinical practice, and biopharmaceutical R&D and manufacturing
.
After years of industry precipitation and development, ISKCON currently employs more than 1,500 people around the world, and its sales network covers more than 130 countries/regions around the world
.
In 2021, ISKCON completed a $200 million Series A financing led by Vivo Capital and Novo Holdings A/S, with investors including EDBI (an investment company under the Singapore Economic Development Board) , China Investment Corporation and other well-known investors, officially entered the group development 3.
0 stage
.
ISK Bio's vision is to use Singapore as the link between East and West, leveraging its years of global business development and operational experience to promote the integration of the life sciences to build a global life sciences ecosystem
.